These results demonstrate that GSK3 inhibitors, namely GSK3α and β, that downregulate PD-1 expression can enhance CD8+ T cells function to a similar extent to PD-1 blocking antibodies, which offer novel approaches in cancer immunotherapy [158]. The gene discussed is PDCD1; the disease is cancer.